Janus Henderson Group PLC Has $490.13 Million Stock Holdings in Waters Corporation $WAT

Janus Henderson Group PLC lessened its position in Waters Corporation (NYSE:WAT) by 0.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,290,393 shares of the medical instruments supplier’s stock after selling 12,040 shares during the quarter. Janus Henderson Group PLC owned approximately 2.17% of Waters worth $490,130,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Norges Bank bought a new position in Waters in the fourth quarter valued at approximately $265,751,000. Veritas Asset Management LLP grew its stake in Waters by 112.3% in the fourth quarter. Veritas Asset Management LLP now owns 1,241,206 shares of the medical instruments supplier’s stock valued at $471,447,000 after purchasing an additional 656,436 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Waters by 509.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 671,103 shares of the medical instruments supplier’s stock valued at $254,906,000 after purchasing an additional 561,047 shares in the last quarter. Marshall Wace LLP grew its stake in Waters by 1,611.3% in the fourth quarter. Marshall Wace LLP now owns 581,063 shares of the medical instruments supplier’s stock valued at $220,705,000 after purchasing an additional 547,109 shares in the last quarter. Finally, Invesco Ltd. grew its stake in Waters by 32.3% in the third quarter. Invesco Ltd. now owns 1,472,419 shares of the medical instruments supplier’s stock valued at $441,446,000 after purchasing an additional 359,596 shares in the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.

Analysts Set New Price Targets

WAT has been the subject of a number of analyst reports. TD Cowen raised their price target on Waters from $345.00 to $385.00 and gave the company a “hold” rating in a research note on Wednesday, May 6th. Bank of America raised their price target on Waters from $370.00 to $400.00 and gave the company a “neutral” rating in a research note on Tuesday, June 2nd. Piper Sandler initiated coverage on Waters in a research note on Thursday, June 11th. They issued a “neutral” rating and a $400.00 price target for the company. Morgan Stanley decreased their price target on Waters from $423.00 to $350.00 and set an “equal weight” rating for the company in a research note on Sunday, February 22nd. Finally, Wolfe Research assumed coverage on Waters in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $425.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Waters presently has an average rating of “Moderate Buy” and a consensus target price of $394.56.

Waters Stock Performance

WAT opened at $357.02 on Thursday. The business has a fifty day simple moving average of $340.94 and a 200 day simple moving average of $348.84. The company has a market capitalization of $35.06 billion, a PE ratio of 45.36, a price-to-earnings-growth ratio of 2.18 and a beta of 1.21. Waters Corporation has a 1 year low of $275.05 and a 1 year high of $414.15. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13.

Waters (NYSE:WAT) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.31 by $0.39. The business had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.20 billion. Waters had a return on equity of 15.60% and a net margin of 11.91%.The firm’s quarterly revenue was up 91.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.25 EPS. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Research analysts expect that Waters Corporation will post 14.51 EPS for the current year.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.